State Street Corp Boosts Stake in Kodiak Sciences Inc. (NASDAQ:KOD)

State Street Corp grew its stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 1.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 816,634 shares of the company’s stock after buying an additional 14,711 shares during the period. State Street Corp’s holdings in Kodiak Sciences were worth $2,131,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new stake in shares of Kodiak Sciences during the third quarter valued at $33,000. Meeder Asset Management Inc. purchased a new position in Kodiak Sciences in the 2nd quarter valued at about $36,000. Sanctuary Advisors LLC acquired a new stake in shares of Kodiak Sciences during the 2nd quarter worth about $36,000. LJI Wealth Management LLC grew its holdings in shares of Kodiak Sciences by 21.3% during the third quarter. LJI Wealth Management LLC now owns 17,100 shares of the company’s stock worth $45,000 after buying an additional 3,000 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Kodiak Sciences in the second quarter valued at approximately $127,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Kodiak Sciences Stock Performance

Shares of KOD stock opened at $9.95 on Thursday. The firm has a market capitalization of $523.61 million, a price-to-earnings ratio of -2.73 and a beta of 2.38. Kodiak Sciences Inc. has a one year low of $2.18 and a one year high of $11.60. The company has a 50 day moving average price of $6.75 and a 200 day moving average price of $4.12.

Analyst Ratings Changes

A number of analysts recently issued reports on KOD shares. Barclays raised their target price on shares of Kodiak Sciences from $3.00 to $4.00 and gave the stock an “underweight” rating in a research report on Friday, November 15th. Jefferies Financial Group raised Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Monday, December 9th. Finally, HC Wainwright reiterated a “neutral” rating and set a $3.00 target price on shares of Kodiak Sciences in a research report on Friday, November 15th.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.